

**Experiment Number:** S0548  
**Route:** Gavage, IV  
**Species/Strain:** Rat/Fischer 344

**Toxicokinetics Data Summary**  
**Test Compound:** Sodium Nitrite  
**CAS Number:** 7632-00-0

**Date Report Requested:** 12/02/2016  
**Time Report Requested:** 11:52:24  
**Lab:** Midwest Research Institute

**Male**

**Treatment Groups (mg/kg)**

	<b>40<sup>a, #</sup></b>	<b>40<sup>b, *</sup></b>	<b>80<sup>a, #</sup></b>	<b>80<sup>b, *</sup></b>	<b>20 IV<sup>a, #</sup></b>	<b>20 IV<sup>c, *</sup></b>
<b>Plasma</b>						
C <sub>max</sub>	18.8 percent	2.5 ug/mL	40.1 percent	11 ug/mL	26.3 percent	35 ug/mL
T <sub>max</sub> (minute)	60.0	8.8	120.0	17.0	45.0	
t <sub>1/2</sub> (minute)	50		75		53	
t <sub>1/2</sub> (Alpha) (minute)						1.5
t <sub>1/2</sub> (Beta) (minute)						52.0
t <sub>1/2</sub> (k <sub>01</sub> ) (minute)		79		2.9		
t <sub>1/2</sub> (k <sub>10</sub> ) (minute)		1.5		144		9.1
k <sub>12</sub> (min <sup>-1</sup> )						0.32
k <sub>21</sub> (min <sup>-1</sup> )						0.081
V <sub>1</sub> (mL)		15.0		1400.0		91.0
MRT (minute)	117		171		94	
AUC <sub>0-t</sub> (percent min)	2620		10500.0		3260	
AUC <sub>inf</sub> (ug*min/mL)		308.0		2550.0		454.0
F (percent)		34.0		140.0		

**Experiment Number:** S0548  
**Route:** Gavage, IV  
**Species/Strain:** Rat/Fischer 344

**Toxicokinetics Data Summary**  
**Test Compound:** Sodium Nitrite  
**CAS Number:** 7632-00-0

**Date Report Requested:** 12/02/2016  
**Time Report Requested:** 11:52:24  
**Lab:** Midwest Research Institute

---

<b>Female</b>						
<b>Treatment Groups (mg/kg)</b>						
	<b>40 a, #</b>	<b>40 b, *</b>	<b>80 a, #</b>	<b>80 b, *</b>	<b>20 IV a, #</b>	<b>20 IV b, *</b>
<b>Plasma</b>						
C <sub>max</sub>	31.5 percent	12 ug/mL	65.9 percent	32 ug/mL	25.8 percent	11 ug/mL
T <sub>max</sub> (minute)	60.0	13.0	120.0	28.0	45.0	
t <sub>1/2</sub> (minute)	73		81		82	
t <sub>1/2(k01)</sub> (minute)		3.7		8.4		
t <sub>1/2(k10)</sub> (minute)		35		60		49
V <sub>1</sub> (mL)		140		250		200
MRT (minute)	125		186		130	
AUC <sub>0-t</sub> (percent min)	5480		16400.0		4340	
AUC <sub>inf</sub> (ug*min/mL)		770		3840		796
F (percent)		52		130		

---

**Experiment Number:** S0548  
**Route:** Gavage, IV  
**Species/Strain:** Rat/Fischer 344

**Toxicokinetics Data Summary**  
**Test Compound:** Sodium Nitrite  
**CAS Number:** 7632-00-0

**Date Report Requested:** 12/02/2016  
**Time Report Requested:** 11:52:24  
**Lab:** Midwest Research Institute

## LEGEND

---

Data are displayed as a mean value

### MODELING METHOD & BEST FIT MODEL

- <sup>a</sup> PCNONLIN Statistical Consultants, Inc., Lexington, KY; Non compartmental (NCA) model
- <sup>b</sup> PCNONLIN Statistical Consultants, Inc., Lexington, KY; One compartment model
- <sup>c</sup> PCNONLIN Statistical Consultants, Inc., Lexington, KY; Two compartmental model

### ANALYTE

- # Methemoglobin
- \* Nitrite

### TK PARAMETERS

$C_{max}$  = Observed or Predicted Maximum plasma (or tissue) concentration

$T_{max}$  = Time at which  $C_{max}$  predicted or observed occurs

$t_{1/2}$  =  $\lambda_{z}$  half-life,  $t_{1/2}$ , the terminal elimination half-life based on non-compartmental analysis

$t_{1/2(\alpha)}$  = Half-life for the alpha phase

$t_{1/2(\beta)}$  = Half-life for the beta phase

$t_{1/2(k_{01})}$  = Half-life of the absorption process to the central compartment

$t_{1/2(k_{10})}$  = Half-life for the elimination process from the central compartment

$k_{12}$  = Distribution rate constant from first to second compartment etc.

$k_{21}$  = Distribution rate constant from second to first compartment etc.

$V_1$  = Volume of distribution of the central compartment, includes  $V_d$  and  $V_{volume}$  of distribution,  $V_z$  apparent volume of distribution NCA,  $V_{app}$  apparent volume of distribution for intravenous studies

MRT = Mean residence time

$AUC_{0-t}$  = Area under the plasma concentration versus time curve, AUC, from time  $t_i$  (initial) to  $t_f$  (final),  $AUC_{last}$

$AUC_{inf}$  = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

**\*\* END OF REPORT \*\***